Appointment of Anesh Patel as Chief Financial Officer and Company Secretary
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, is pleased to announce that further to previous announcements, Anesh Patel has been appointed to the board of directors as Chief Financial Officer and Company Secretary with immediate effect.
Anesh Patel was appointed as Chief Financial Officer of Feedback's wholly owned subsidiary, Feedback Medical Limited, in May 2021 as part of a succession planning programme following Lindsay Melvin's (Chief Financial Officer and Company Secretary of Feedback) decision to retire from the board of Feedback during H2 2021. Anesh has worked alongside Lindsay over the past months to ensure a smooth and orderly transition.
Anesh joined Feedback Medical Limited from hVIVO Limited, a subsidiary of AIM-listed Open Orphan plc and a rapidly growing, industry-leading, clinical services provider to pharma, biotech and government organisations where most recently he was finance & corporate projects director. Prior to hVIVO, he spent seven years in investment banking where he specialised in corporate finance advisory services, at leading banks including Société Générale and Standard Bank. Anesh started his professional career with Ernst & Young in 2004 where he qualified as a chartered accountant, initially working within the audit & assurance division before transferring to the transaction support team for private equity clients. He graduated from University College London (UCL) and holds an M.Sci. (Hons) degree in Mathematics with Economics.
Rory Shaw, Chairman of Feedback, commented: "We welcome Anesh to the Board of Feedback. He joined the team earlier this year and has already proven the value he brings through his contribution to the successful £11.2 million fundraise recently announced. His broad financial and commercial experience provides a good balance to the medical and technical expertise we have across the Board, creating a strong team to take the Company forward. I would also like to take this opportunity to thank Lindsay for his work guiding the Company through its formative years, and for enabling a smooth handover to ensure Feedback continues on this trajectory of growth. We believe that Feedback is set for a bright and exciting future ahead."
Aneshkumar (Anesh) Ishwarbhai Patel (aged 40) does not currently hold any directorships and has no previous directorships (within 5 years). Anesh Patel has confirmed that there is no further information to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules.
Tom Oakley, CEO
Anesh Patel, CFO
+44 (0)1954 718072
| || |
Panmure Gordon (UK) Limited (NOMAD and Broker)
Emma Earl/Freddy Crossley (Corporate Finance)
Rupert Dearden (Corporate Broking)
+44 (0)20 7886 2500
| || |
Walbrook PR Ltd
Tel: 020 7933 8780 or email@example.com
Paul McManus/Nick Rome/Nicholas Johnson
07980 541 893 or 07748 325 236 or 07884 664 686
Notes to Editors
Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.